Ando Tomo, Briasoulis Alexandros, Holmes Anthony A, Afonso Luis, Schreiber Theodore, Kondur Ashok
Wayne State University, Detroit Medical Center, Division of Cardiology, Detroit, MI 48226, USA.
Wayne State University, Detroit Medical Center, Division of Cardiology, Detroit, MI 48226, USA.
Int J Cardiol. 2016 Jul 15;215:14-9. doi: 10.1016/j.ijcard.2016.04.033. Epub 2016 Apr 12.
Patients with severe aortic stenosis (AS) and previous coronary artery bypass graft (CABG) surgery have increased risk for aortic valve replacement. Whether surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) offers better outcomes in this population is unclear. We aimed to assess outcomes of TAVR and SAVR in patients with previous CABG.
A systematic literature search of Medline, EMBASE and Cochrane library was conducted. Studies that reported clinical outcomes (perioperative or mid-term all-cause-mortality, cardiovascular mortality, pacemaker implantation, hospital duration and stroke) were included. Random-effect modeling was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs).
Five cohort studies including a total of 872 patients (423 in TAVR, 449 in SAVR) were analyzed. STS scores were comparable between the two groups. No difference in all-cause-mortality, cardiovascular mortality and stroke at 30days, 1year and total follow-up period was seen between the two groups. TAVR patients had higher pacemaker implantation rates (OR 3.41, 95% CI 1.66-6.38, p<0.001, I(2)=21%) and shorter hospital stay (-2.63days, 95% CI -5.20 to -0.04, p=0.05, I(2)=43%).
Patients with previous CABG who underwent TAVR had similar perioperative and long-term survival while experiencing more pacemaker implantations and shorter hospital stay compared to those who had SAVR making TAVR a safe and efficacious alternative to SAVR.
患有严重主动脉瓣狭窄(AS)且曾接受冠状动脉旁路移植术(CABG)的患者,主动脉瓣置换术的风险增加。在这一人群中,外科主动脉瓣置换术(SAVR)或经导管主动脉瓣置换术(TAVR)哪种能带来更好的结果尚不清楚。我们旨在评估曾接受CABG的患者接受TAVR和SAVR的结果。
对Medline、EMBASE和Cochrane图书馆进行了系统的文献检索。纳入报告临床结果(围手术期或中期全因死亡率、心血管死亡率、起搏器植入、住院时间和中风)的研究。采用随机效应模型计算比值比(OR)和95%置信区间(CI)。
分析了5项队列研究,共872例患者(TAVR组423例,SAVR组449例)。两组的胸外科医师协会(STS)评分相当。两组在30天、1年和总随访期的全因死亡率、心血管死亡率和中风方面无差异。TAVR患者的起搏器植入率更高(OR 3.41,95%CI 1.66 - 6.38,p<0.001,I²=21%),住院时间更短(-2.63天,95%CI -5.20至-0.04,p=0.05,I²=43%)。
与接受SAVR的患者相比,曾接受CABG并接受TAVR的患者围手术期和长期生存率相似,但起搏器植入更多,住院时间更短,这使得TAVR成为SAVR的一种安全有效的替代方案。